Additional file 1: of Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

Curtis, Jeffrey; Winthrop, Kevin; OâBrien, Cathy; Ndlovu, Matladi; de Longueville, Marc; Haraoui, Boulos

doi:10.6084/m9.figshare.5708740.v1

13075_2017_1466_MOESM1_ESM.pdf (528.6 kB)

Additional file 1: of Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

journal contribution

posted on 2017-12-15, 05:00 authored by Jeffrey Curtis, Kevin Winthrop, Cathy OâBrien, Matladi Ndlovu, Marc de Longueville, Boulos Haraoui

Methods: testing of RABBIT Risk Score in the All CZP group. Table S1. Observed number of SIEs in patients categorized by AACI. Figure S1. Predicted and observed SIE rates in All CZP patients according to the RABBIT Risk Score. (PDF 178 kb)

Funding

UCB

History

Usage metrics

Read the peer-reviewed publication

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

Arthritis Research & Therapy

Keywords

Certolizumab pegol Safety Global risk score Comorbidity Serious infection

Licence

CC BY + CC0

Additional file 1: of Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

Funding

UCB

History

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports